J. Goldman & Co’s Anterix ATEX Stock Holding History

J. Goldman & Co’s Portfolio ATEX Stock Details ATEX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-9,033	Closed	-$345K	–	714
2026 Q1	$345K	Buy	+9,033	New	+$286K	0.01%	550

Other funds holding ATEX

OCAM

Owl Creek Asset Management New York $1.21B AUM 169.99% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

HCL

Heard Capital LLC Chicago, Illinois $2.34B AUM 46.76% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Plustick Management Charlottesville, Virginia $269M AUM 340.55% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

GAMCO Investors Greenwich, Connecticut $11.1B AUM 41.79% 1-Year Est. Return

J. Goldman & Co's ATEX Position: Q2 2026 in Review

J. Goldman & Co sold out of Anterix (ATEX) in Q2 2026, closing a stake of 9,033 shares — an estimated $345K sold.

J. Goldman & Co first reported a position in ATEX in Q1 2026 and held it in 1 quarter. The position peaked at $345K in Q1 2026. 171 funds tracked by Wall St. Rank hold ATEX as of Q2 2026.

J. Goldman & Co reported no remaining Anterix position as of Q2 2026 after selling out during the quarter.
J. Goldman & Co sold 9,033 Anterix shares in Q2 2026, an estimated $345K.
J. Goldman & Co first reported a position in Anterix in Q1 2026 and held it in 1 quarter.
J. Goldman & Co's Anterix position peaked at $345K in Q1 2026.
171 funds tracked by Wall St. Rank held Anterix as of Q2 2026.

Based on J. Goldman & Co's 13F filing for Q2 2026, filed 14 Aug 2026.